Jaleva’s platform technology can be applied almost anywhere on the body, including in the mouth. Trans-mucosal delivery of drugs to the bloodstream broadens the range of deliverable drugs. In comparison to skin, intra-oral mucosa is more permeable to medications.
The Company’s resin technology is a biodegradable transport vehicle that enhances a drug’s release. Current patch delivery systems have matrix polymers that trap drugs and prevent them from being released effectively. The Company’s technology promotes greater drug mobility than matrix polymers, resulting in better drug release. Jaleva’s technology also facilitates the drug slipping through the outer layer of the mucosa and subsequently into the bloodstream.
Recent in vivo studies have shown a TMAX of under 10 minutes on delivery of active ingredients into the bloodstream.
Many topical dermatologic treatments use delivery vehicles such as powders, sprays, solutions, lotions, lacquers and creams to deliver an active ingredient to the skin. However, these delivery vehicles often lack effectiveness as the application of the product comes off easily once applied to an affected area of the skin and, this in combination with trapping of the active ingredient by the vehicle, results in poor delivery of the active medication.
Jaleva’s resin technology is applied to the skin or mucosa as a liquid, which dries after a period of 30-45 seconds to form a medicated film. This film is comprised of millions of micro-droplets of resin. Each droplet contains an inert concentration of the formulation’s active ingredient. The resin does not degrade the active ingredient. In fact, the resin promotes drug release into the epidermis and dermis. The active ingredient is released over time according to the relative concentrations of drug and resin. Jaleva’s resin technology has proven to be 3-5 times more effective than other vehicles (e.g. creams, powders, gels, and lacquers) in delivering medication to the different layers of the skin.
